Genomic profiling of UC has revealed common potentially actionable genomic alterations, indicating potential target therapies with driver molecular alterations, including fibroblast growth factor receptor (FGFR), human epidermal growth factor receptor 2 (HER2), and tumor mutational burden (TMB).11, 14, 15. Here, ERBB2 is linked to neoplasm.